The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I didn’t know exactly what this relates to so I looked it up . Very interesting!..........Ischemia-reperfusion injury is a common feature of ischemic stroke, which occurs when blood supply is restored after a period of ischemia. Reperfusion can be achieved either by thrombolysis using thrombolytic reagents such as tissue plasminogen activator (tPA), or through mechanical removal of thrombi. Spontaneous reperfusion also occurs after ischemic stroke.
This is a medical intervention treatment. A drug.
It's very interesting that massive doses have a direct influence on sufferers of this horrendous condition.
I hope that the human trials can follow and that a life enhancing benefit can be added to the growing list.
Obviously, that would bring a financial gain, but I'm more excited over the possibility of such a breakthrough medically.
It's a good Conclusion to the Patent application.
In conclusion, under the experimental condition, the water-soluble tomato concentrate has remarkable repairing effect on rat MCAO/R injury, can remarkably reduce cerebral infarction area, reduce nerve function score, improve brain tissue pathology and increase cerebral blood flow on the side of ischemia.
One of my long held thoughts is that the short to medium term value of the provexis stock lies in the underlying asset of the patents held by the Company. As time goes on the number of worldwide patents has increased and has started to cover an increasing number of uses. Furthermore, the recent "Clinical Trials" performed by BH, would appear to be positive and will only add to the value of the previous trials required to gain the original EFSA approval.
In my very simplistic mind, I have ascribed an approximate value to these patents/IP of £40-50M. The current market value of the Company is £14.5M and so, I believe that there is significant hope of short to medium growth in the share price.
The share price has been held back because of the lack of a positive marketing plan for the original product and the threat of a funding shortfall.
However there are now a number of issues on the horizon that could breakthrough the negativity:
1) The possibility that provexis could move into profitability in the next 12 months
2) The grant of Blue Cap Status for the use of Fruitflow in the Chinese Market. Not only would this increase the value of the IP but it would also open up a massive new market for the product.
3) We now have two more potential uses for the product: Gut health (being investigated via DSM and; Possible drug claims under the new BH patent.
I continue to keep my fingers crossed that I am right with these thoughts, but it has been a very long time coming.
"thoughts"
Yes it would be good if Provexis had applied for this patent but By-Health have put in the work and paid for it. Provexis cant patent FF for every scenario.
"Who would benefit"
Well you can only assume By-Health for holding the patent and Provexis for supplying the FF.
Slam it makes little difference who has applied for patent as By health can only buy ff from pxs , so the more they need the more bottom line for pxs .
It would be great news if this was a precursor to an entry into the "Drugs Market".
However, I am slightly concerned that it is BH who have applied for a patent, rather than Provexis. Who would benefit from such a patent, if granted? Any thoughts?
It does. 👍
Sounds like a great candidate for a drug !
Gixer great find , reading through that it implies the dosage should be upto 150mg per Kg of weight so a 80kg man would need a lot of ff for the dosage to work
"Specifically, the oral or injectable administration forms of the above composition for treating cerebral ischemia-reperfusion injury include solutions, powders, tablets, granules, capsules, emulsions and suspensions. It will be appreciated that the above-described compositions for treating cerebral ischemia-reperfusion injury may be administered by subcutaneous injection, intra-cerebral administration, intravenous injection, oral administration, or the like."
"In a specific example, the dosage of the water-soluble tomato concentrate in the composition for treating cerebral ischemia-reperfusion injury is 15mg/kg to 150mg/kg. Alternatively, the dose of water-soluble tomato concentrate in the composition for treating cerebral ischemia-reperfusion injury is 47.25mg/kg. It will be appreciated that the specific concentration may be adjusted as desired depending on the condition or individual situation."
Use of water-soluble tomato concentrate in preparation of composition for treating cerebral ischemia-reperfusion injury
https://patents.google.com/patent/CN116688025A/en?q=(%22water-soluble+tomato%22)&oq=%22water-soluble+tomato%22&sort=new
"Based on this, the application provides a new use of a water-soluble tomato concentrate, relating to the use of a water-soluble tomato concentrate in the preparation of a composition for preventing, alleviating or treating cerebral ischemia-reperfusion injury."
"Abstract
The present application relates to the use of a water-soluble tomato concentrate for the preparation of a composition for the treatment of cerebral ischemia-reperfusion injury. Through long-term research, researchers of the application firstly find and prove that the water-soluble tomato concentrate has obvious repairing effect on ischemic cerebral apoplexy reperfusion injury according to nerve function evaluation, tetrazolium red staining and HE staining, can obviously reduce cerebral infarction area, reduce nerve function score and improve brain tissue pathology, and can be applied to preparing a composition for treating cerebral ischemia-reperfusion injury."
:-)
1m trade is going on, which is Very Interesting Trade.
This page outlines the process in a flow chart. Section 2.
https://www.cirs-group.com/en/food/products-with-the-new-health-function-claims-are-being-possible-in-china
Thanks for that Dr H. I was wondering whether it would go to the back of the queue on the back of any claims already lodged for the other 24 claim categories. It would be unusual for them to have a separate department for new claims beyond the 24?
The BlueHat claims can have a large lead time. However, BH have most of the work for the testing required etc. Therefore, they only need the tail end of the process, so probably < 6 months.
There has never been a new functional claim previously, so no precedent. There is noting in the queue in front of it, as BH are the first to apply. We know that SAMR have been involved throughout, so their response timeline should be quite reasonable.
The whole lot has been submitted together. I am thinking it may take up to 3 months. Not sure what other people's views are.
Very sorry if this has been covered recently but what is the best guess on approvals from SAMR for Blue Hat? Standard claims appear to take anywhere between 1-3 years but has there been any indication of timescale for the new function claims? Many thanks in advance.
A Chinese company like BH spend eight years of time and millions of £ of their own money not for fun. I know the Chinese very well as first part of career was working with Chinese for sometime and they will not put money if they are not 100% sure that they will get a very very good return. As I said before time will tell the truth. 18P please.
Re: "hopefully the deal with BH is better than the deal with DSM"
I doubt we will ever find out what price we sell Fruitflow to either B-H, DSM or anyone else for that matter.
Sorry Sir:I will obviously ask permission from you as to when and what I can post KOK X No need to reply as I have now filtered you 😉
Groan !!!
DSM are applying for new IP patents regarding gut health.
We HAVE been informed of that.
Years away from commercial products appearing.
Your wish to have the last word is a bit tiring.
Obviously nothing of financial interest in the DSM deal then?
Received this email today , seems to be a big deal in China ! "...........China's Registration Channel of Health Food Reopens
as Disclosed by a Series of Key Regulations
📣 Recently, China has released a series of key regulations to develop the Chinese health food industry. Let's take a look!
On August 28, 2023, the State Administration for Market Regulation (SAMR) of China published Detailed Rules on the Implementation of Technical Evaluation on New Functions and Health Food with New Functions (Trial), with immediate effect. This Regulation introduces a new management model of new functions for health food in China, aiming to encourage industries to engage in functional innovation and product R&D.
Just one day after, on August 29, 2023, BYHEALTH (汤臣倍健), one of the giant health supplement companies based in China, submitted an application for the new healthcare function "helping maintain normal platelet aggregation function, which is beneficial for blood flow health", being the first mover under the new management mechanism.
Later on August 31, 2023, SAMR published five regulations concerning health food with immediate effect, they are:
- Health Function Catalogue Allowed for Health Food Claims Non-Nutrient Supplement (2023)
- Evaluation and Testing Method for Health Food Functions (2023)
- Technical Guideline for Evaluation and Testing of Health Food Functions (2023)
- Ethical Review Guideline for Health Food Human Consumption Test (2023)
- Interpretations on Health Function Catalogue Allowed for Health Food Claims Non-Nutrient Supplement (2023) and Its Supportive Documents
The release of these regulations signifies the reopening of the registration mechanism by Chinese authorities, which is highly beneficial for health food enterprises, as product filing has been the predominant method for market access to health food.
📣 To help you better understand these regulations, ChemLinked prepares English Translations of the most noteworthy ones, as well as insightful upcoming webinars to allow you to apply your knowledge in real-world situations. Don't miss out on this opportunity to gain a competitive edge!
Not so.
If there was something of significance financially, then the company has a duty to report that to the market.
You know how these things work, you've been around long enough.
Even if it was "bolted on"know one will know the deal!!